

Name:	Dr. Nai-Jung Chiang	Date: (YYYY/MM/DD)	2023/02/19	
Department:	Department of Oncology	Position:	Attending physician	
Email:	njchiang@vghtpe.gov.tw	Contact #:	8#1092	
Education:	Ph.D. Institute of Clinical Medicine, College of Medicine, National Cheng Kung University M.D. National Defense Medical Center, Taipei, Taiwan			
Experience:	<p>2022.03-now Attending Physician, Department of Oncology, Taipei Veterans General Hospital. Adjunct Assistant Investigator & Attending physician, National Institute of Cancer Research, NHRI.</p> <p>2020.4-2022.02 Assistant Investigator & Attending physician, National Institute of Cancer Research, NHRI. Attending physician, Department of Oncology, National Cheng Kung University hospital.</p> <p>2013.7-2020.3 Attending physician, National Institute of Cancer Research, NHRI & Department of internal medicine, National Cheng Kung University hospital.</p> <p>2010.9-2013.6 Fellowship, National Institute of Cancer Research, NHRI, Tainan, Taiwan. Attending physician, Department of internal medicine, National Cheng Kung University hospital.</p> <p>2008.9-2010.8 Chief Resident, Division of Oncology-Hematology, Department of internal medicine, National Cheng Kung University hospital and National Institute of Cancer Research, NHRI.</p>			
Research Interests: (Key words)	Pancreatic cancer/biliary tract cancer/gastric cancer/esophageal cancer/clinical trial			
Selected Publications (in recent 5 yr):	<ol style="list-style-type: none"> Chueh CH, Tsai YW, Chen ZR, Shiu MN, Wen YW, Chiang NJ*. Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. <i>Pharmacoeconomics</i>. 41(3):307-319. doi:10.1007/s40273-022-01227-6, 2023. (corresponding author) Su YY*, Chiang NJ*, Chang JS, Wang YW, Shen BN, Li YJ, Hwang DY, Shan YS, Chen LT. The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. <i>ESMO Open</i>. 8(1):100746, 2022. (*Co-first author) Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, Chen MH. Impaired Chromatin Remodeling Predicts Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. <i>Clin Cancer Res</i>. 28(19):4248-4257, 2022. Chiang NJ, Shan YS, Li CP, Yang SH, Su YY, Chiu SZ, Bai LY, Chuang SC, Chan DC, Yen CJ, Peng CM, Chiu TJ, Chen YY, Chen JS, Chou WC. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma. <i>Am J Cancer Res</i>. 12(11):5062-5073, 2022. 			

5. **Chiang NJ**, Hou YC, Tan KT, Tsai HW, Lin YJ, Yeh YC, Chen LT, Hou YF, Chen MH, Shan YS. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma. *Hepatology International*. 16(5):1137-1149, 2022.
6. Su YY*, **Chiang NJ***, Li CP, Yen CJ, Yang SH, Chou WC, Chen JS, Chiu TJ, Chen YY, Chuang SC, Bai LY, Chiu CF, Peng CM, Chan DC, Chiu SC, Yang YH, Shan YS, Chen LT. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. *Front Oncol*. 12:800842, 2022. (*Co-first author)
7. Yang SH*, **Chiang NJ***, Chiu SC, Chou WC, Bai LY, Li CP, Su YY, Chiu TJ, Chuang SC, Peng CM, Chan DC, Chen JS, Yen CJ, Chen YY, Chiu CF, Chen LT, Shan YS. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. *Am J Cancer Res*. 12(4):1884-1898, 2022. (*Co-first author)
8. Gopinathan P*, Liu CH*, **Chiang NJ***, Huang CJ, Tu HC, Hung SC, Shan YS, Lee GB. Exfoliated tumor cells in bile as a promising indicator of disease status in cholangiocarcinoma. *Sensors and Actuators B: Chemical*. 346: 130526, 2021. (*Co-first author)
9. Chang KY, **Chiang NJ**, Wu SY, Yen CJ, Chen SH, Yeh YM, Li CF, Feng X, Wu Katherine, Amanda Johnston, John S Bomalaski, Wu BW, Gao J, Sumit K Subudhi, Ahmed O Kaseb, Jorge M Blando, Shalini S Yadav, Peter W Szlosarek, Chen LT. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. *Oncoimmunology*. 12;10(1):1943253, 2021.
10. Wang YL, Jhang DF, Tsai CH, **Chiang NJ**, Tsao CH, Chuang CC, Chen LT, Chang WS, Liao LD. In Vivo Assessment of Hypoxia Levels in Pancreatic Tumors Using a Dual-Modality Ultrasound/Photoacoustic Imaging System. *Micromachines (Basel)*. 12(6):668, 2021.
11. **Chiang NJ**, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. *Biomolecules*. 13;11(1):97, 2021.
12. Shiah HS*, **Chiang NJ***, Lin CC, Yen CJ, Tsai HJ, Wu SY, Su WC, Chang KY, Wang CC, Chang JY, Chen LT. Phase I dose escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors. *The Oncologist*. 26(4):e567-e579. doi:10.1002/onco.13612, 2021. (*Co-first author)
13. Gopinathan P*, **Chiang NJ***, Wang CH, Sinha A, Tsai YC, Tu HC, Hung SC; Hsu PH, Shan YS, Lee GB. Aptamer probed isolation of circulating tumor cells in cholangiocarcinoma patients. *Sensors and Actuators B: Chemical*. 322: 128569, 2020. (*Co-first author)
14. **Chiang NJ**, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS, Shan YS, Chen LT. Multicentre, Phase II Study of Gemcitabine and S-1 in Patients With Advanced Biliary Tract Cancer: TG1308 Study. *Liver Int*. 40(10):2535-2543, 2020.
15. **Chiang NJ**, Tsai KK, Chen JS, Yang SH, Hsiao HH, Shan YS, Chen LT. A Multicenter, Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine in Metastatic Pancreatic Adenocarcinoma -TCOG T1211 Study. *European Journal of Cancer*. 124: 123-130, 2020.
16. Gopinathan P*, **Chiang NJ***, Bandaru A, Sinha A, Huang WY, Hung SC, Shan YS, Lee GB. Exploring Circulating Tumor Cells in Cholangiocarcinoma Using a Novel Glycosaminoglycan Probe on a Microfluidic Platform. *Adv Healthc Mater*. 9(10): e1901875, doi: 10.1002/adhm.201901875, 2020. (*Co-first author)

Names of Lab members:

Violet Lu & Miss Chao